Breeze Holdings Acquisition Corporation (Ord) · Breeze Holdings Acquisition Corporation (Rights) · Breeze Holdings Acquisition Corporation (Warrants) 

Rights issue rationale ONXEO targets to become a global leader in oncology, with a focus on orphan or rare cancers, leveraging its three key programs already at an advanced development stage, Beleodaq® (an approved histone deacetylase inhibitor (HDAC) commercialized in the US by partner Spectrum Pharmaceuticals for .

(3) Capital increase up to 100% This rights issue will allow us to pursue this step-up, by accelerating and expanding development programs which are the base of ONXEO value. » (Judith Greciet, CEO of ONXEO). Rights issue main terms This capital increase with shareholder preferential subscription rights will result in the issuance of Onxeo Launches a Rights Issue to Accelerate Its R&D Programs Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage 16 timmar sedan · Zeit Aktuelle Nachrichten; 13:51: Onxeo S.A.: Onxeo Announces the Success of Its Rights Issue With €9.7 Million Raised: This transaction will accelerate the development of the Company and its 4 timmar sedan · Onxeo Announces the Success of Its Rights Issue With €9.7 Million Raised Bioalliance PharmaAct Nom Cat-P Aktie [Valor: 1884147 / ISIN: FR0010095596] Kaufen Verkaufen 16 timmar sedan · Onxeo Announces the Success of Its Rights Issue With €9.7 Million Raised Regulatory News: Do not distribute or disseminate, directly or indirectly, in the United States of America, Canada 1 month Onxeo Launches a Rights Issue to Accelerate Its R&D Programs Business Insider